Moderna, Inc. — Director's Dealing 2021

Jan 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-07-06

Reporting Person: Meline David W (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-06	Stock Option (Right to Buy)	$59.15	A	271303	Acquired	2030-07-06	Common Stock (271303)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on July 6, 2021 with the remainder vesting in 12 equal quarterly installments thereafter.